Alkermes (ALKS)

Company Description

Alkermes plc is a fully integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to develop innovative medicines that improve patient outcomes. The company has a diversified portfolio of more than 20 commercial drug products and a substantial clinical pipeline of product candidates that address central nervous system (CNS) disorders such as addiction, schizophrenia and depression. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and manufacturing facilities in Gainesville, Georgia and Wilmington, Ohio.

 

COMPANY ADDRESS
852 Winter Street
Waltham, MA 02451
United States

COMPANY PHONE
781-609-6000

COMPANY WEBSITE


Get BioInvest's perspective on Alkermes' CEO

Latest Company News

Alkermes PLC (NASDAQ:ALKS) Sentiment Report Weekly Register - 2 hours ago Alkermes PLC (NASDAQ:ALKS) institutional sentiment decreased to 0.91 in Q4 2016. Its down -0.29, from 1.2 in 2016Q3. The ratio is negative, as 111 active investment managers increased and started new positions, while 122 decreased and sold stakes in ... Alkermes PLC (ALKS) Position Decreased by UBS Group AG - The Cerbat Gem Clearbridge Investments LLC Increases Position in Alkermes PLC (ALKS) - BNB Daily (blog) [...]
Tue, Jun 27, 2017 6:40:00 PM, Continue reading at the source
Bullish Chart Formation for Alkermes Plc (ALKS) After Forming Wedge Up Pattern WeeklyHub - Jun 26, 2017 Investors sentiment decreased to 0.91 in 2016 Q4. Its down 0.29, from 1.2 in 2016Q3. It worsened, as 26 investors sold Alkermes Plc shares while 96 reduced holdings. 44 funds opened positions while 67 raised stakes. 138.80 million shares or 2.08% more ... [...]
Mon, Jun 26, 2017 3:22:00 PM, Continue reading at the source
Stock Alert: Alkermes PLC Realized Volatility Hits A Rock Bottom Low CML News - Jun 24, 2017 Before we cover the full analysis we make a quick alert here that Alkermes PLC (NASDAQ:ALKS) has seen its stock price move at a plunging low level. [...]
Sat, Jun 24, 2017 2:03:00 AM, Continue reading at the source
Contrasting Delcath Systems (DCTH) & Alkermes PLC (ALKS) The Cerbat Gem - Jun 22, 2017 Alkermes PLC (NASDAQ: ALKS) and Delcath Systems (NASDAQ:DCTH) are both medical companies, but which is the superior business? [...]
Thu, Jun 22, 2017 8:03:00 PM, Continue reading at the source
Alkermes May Have Lucky Investors Doing A Happy Jig Seeking Alpha - Jun 20, 2017 Ireland-based Alkermes PLC (NASDAQ:ALKS) started as a royalty-based company that reformulated existing drugs into extended release microsphere agents. LS Investment Advisors LLC Has $126000 Stake in Alkermes PLC (ALKS) - The Cerbat Gem Could Alkermes Plc (ALKS) See a Reversal After Having Formed Several Months ... - Weekly Register [...]
Tue, Jun 20, 2017 1:41:00 PM, Continue reading at the source
Option Trading: Alkermes PLC Short Put Spreads and Understanding Earnings CML News - Jun 17, 2017 As we look at Alkermes PLC we note that a short put spread is one of the most common implementations of an option strategy during a bull market, but the analysis completed when employing the short put spread often times lacks the necessary rigor ... [...]
Sat, Jun 17, 2017 5:26:00 PM, Continue reading at the source
Alkermes Looks To Capitalize On Opioid Epidemic Through Aggressive Lobbying Benzinga - Jun 12, 2017 The U.S. Food and Drug Administration's quest to address the growing opioid crisis is hurting many pharmaceutical companies, including Endo International plc - Ordinary Shares (NASDAQ: ENDP), presenting an opportunity for companies like Alkermes Plc ... [...]
Mon, Jun 12, 2017 4:02:00 PM, Continue reading at the source
Alkermes plc (ALKS) Initiates Study 217 for ALKS 5461 for MDD StreetInsider.com - Jun 12, 2017 Alkermes plc (NASDAQ: ALKS) today announced the initiation of study 217, a phase 3b trial of ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD). Alkermes initiates late-stage study of MDD candidate ALKS 5461 - Seeking Alpha [...]
Mon, Jun 12, 2017 10:52:00 AM, Continue reading at the source
Alkermes plc (ALKS) Commences Phase 3 Study of ALKS 3831 in Young Adult Patients StreetInsider.com - Jun 8, 2017 Alkermes plc (NASDAQ: ALKS) today announced the initiation of ENLIGHTEN-Early, a supportive study in the ENLIGHTEN clinical development program for ALKS 3831, an investigational, novel, once-daily, oral atypical antipsychotic drug candidate designed ... [...]
Thu, Jun 08, 2017 11:03:00 AM, Continue reading at the source
Alkermes (ALKS) Up 2.5% Since Earnings Report: Can It Continue? Nasdaq - May 31, 2017 It has been about a month since the last earnings report for Alkermes PLC ALKS . Shares have added about 2.5% in that time frame, outperforming the market. Alkermes plc (ALKS) Moves Lower on Volume Spike for June 05 - Equities.com This is what analysts have to say about Alkermes Plc (NASDAQ:ALKS) after last ... - WeeklyHub [...]
Wed, May 31, 2017 7:30:00 AM, Continue reading at the source